Status: Recruiting
A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.
Participants needed: 54
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Omnix Medical LtdUpdated: Jul 2, 2026Locations: 6
Eligibility criteria
A signed informed consent form. [+5]
Moderate to severe reduction of renal function [+6]